Summary
0OO9 Chart
Fresenius SE & Co. KGaA Dividends
 0OO9 18 May 2023 | Other | €0.92 Per Share |
| 0OO9 16 May 2022 | Other | €0.26 Per Share |
| 0OO9 24 May 2021 | Other | €0.88 Per Share |
| 0OO9 31 Aug 2020 | Other | €0.84 Per Share |
| 0OO9 20 May 2019 | Other | €0.8 Per Share |
Fresenius SE & Co. KGaA Earnings
| 6 Nov 2024 Date | | - Cons. EPS | 0.58 EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
| 17 May 2024 Date | | 0.69 Cons. EPS | - EPS |
| 8 May 2024 Date | | 0.69 Cons. EPS | 0.49 EPS |
| 21 Feb 2024 Date | | 0.76 Cons. EPS | - EPS |
| 0OO9 18 May 2023 | Other | €0.92 Per Share |
| 0OO9 16 May 2022 | Other | €0.26 Per Share |
| 0OO9 24 May 2021 | Other | €0.88 Per Share |
| 0OO9 31 Aug 2020 | Other | €0.84 Per Share |
| 0OO9 20 May 2019 | Other | €0.8 Per Share |
| 6 Nov 2024 Date | | - Cons. EPS | 0.58 EPS |
| 31 Jul 2024 Date | | - Cons. EPS | - EPS |
| 17 May 2024 Date | | 0.69 Cons. EPS | - EPS |
| 8 May 2024 Date | | 0.69 Cons. EPS | 0.49 EPS |
| 21 Feb 2024 Date | | 0.76 Cons. EPS | - EPS |
Fresenius SE & Co. KGaA (0OO9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fresenius SE & Co. KGaA ever had a stock split?
Fresenius SE & Co. KGaA Profile
| Medical Care Facilities Industry | Healthcare Sector | Mr. Michael Sen CEO | LSE Exchange | DE0005785604 ISIN |
| Germany Country | 177,091 Employees | 23 Aug 1970 Last Dividend | - Last Split | - IPO Date |
Overview
Fresenius SE & Co. KGaA is a leading health care company specializing in providing a wide range of products and services for chronically ill patients. With its operations divided into four primary segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed, the company caters to the varied needs of patients worldwide. Fresenius Medical Care focuses on offering solutions for those suffering from chronic kidney failure, while Fresenius Kabi is dedicated to the therapy and care of critically and chronically ill patients through its range of drugs, nutrition products, and medical technologies. Fresenius Helios operates clinical and nursing care facilities, and Fresenius Vamed delivers services for hospitals and other healthcare facilities, including operational management. Established in 1912 and formerly known as Fresenius SE, the company underwent a name change in January 2011 to Fresenius SE & Co. KGaA. Headquartered in Bad Homburg vor der Höhe, Germany, Fresenius stands as a testament to innovation and dedication in the healthcare sector.
Products and Services
- Fresenius Medical Care: Focuses on patients with chronic kidney failure, offering dialysis machines, dialyzers, related disposable products, and dialysis-related services. This comprehensive range is designed to improve the quality of life for patients undergoing dialysis treatment.
- Fresenius Kabi: Specializes in the care of critically and chronically ill patients by providing:
- I.V. Generic Drugs: A variety of intravenous generic medications tailored to meet the needs of patients and healthcare providers.
- Biosimilar Drugs: Treatments for autoimmune diseases and oncology, offering cost-effective alternatives to biologic drugs while maintaining quality and efficacy.
- Enteral and Parenteral Nutrition Products: Essential nutrition solutions for patients who cannot eat normally, ensuring they receive the necessary nutrients.
- Medical Technologies and Disposables: Including infusion pumps, apheresis machines, and cell therapy devices, supporting advanced patient care.
- Fresenius Helios: Provides clinical and nursing care facilities, ensuring high-quality care and services for patients and facilitating a holistic approach to health recovery and management.
- Fresenius Vamed: Offers services for hospitals and other healthcare facilities ranging from operational management to comprehensive care services, aimed at optimizing healthcare delivery and patient experience.
Contact Information
